Condition
Nonalcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownClinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With ObesityNCT07662356 · 2019-12-16
RECRUITINGLanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseNCT03459079 · 2018-08-14
COMPLETEDScreening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 DiabetesNCT03525769 · 2018-05-05
UNKNOWNNonalcoholic Fatty Liver Disease in Morbidly Obese PatientsNCT04059029 · 2016-10-01
UNKNOWNTesamorelin Effects on Liver Fat and Histology in HIVNCT02196831 · 2015-07-01
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
COMPLETED2
UNKNOWN2
RECRUITING1
Phase mix
NA1
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.